Pharma Warns On O'Neill Levy Idea But Wants To Join Global AMR Fight
The drugs industry has slammed the O'Neill AMR Review's proposal that pharma pays for a big part of the bill for tackling antimicrobial resistance – warning it could delay a solution and illustrating how difficult it might be to forge the collective worldwide response that the report calls for.
You may also be interested in...
Many hope the "dialogue of the deaf" between pharma and other healthcare stakeholders can be truly bridged by the industry's latest Davos declaration to collaborate in targeting chronic diseases of the poor.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.